Follicular lymphoma grade III, unspecified, extranodal and solid organ sites
ICD-10 C82.29 is a billable code used to indicate a diagnosis of follicular lymphoma grade iii, unspecified, extranodal and solid organ sites.
Follicular lymphoma grade III is a subtype of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. This specific grade indicates a more aggressive form of the disease, often associated with a higher proliferation index and a poorer prognosis compared to lower grades. The term 'extranodal' refers to the involvement of lymphoid tissue outside of the lymph nodes, which can include organs such as the spleen, liver, or bone marrow. Patients may present with B-symptoms, which include fever, night sweats, and weight loss, indicating systemic involvement. Diagnosis typically involves a combination of imaging studies, biopsy, and histological examination to confirm the presence of neoplastic follicle center cells. Treatment protocols may include chemotherapy, immunotherapy, or targeted therapies, depending on the stage of the disease and the patient's overall health. The management of follicular lymphoma grade III often requires a multidisciplinary approach, involving oncologists, hematologists, and radiologists.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and management of newly diagnosed follicular lymphoma, treatment response evaluation.
Ensure accurate staging and grading are documented to support treatment decisions.
Imaging reports detailing extranodal involvement and staging.
Imaging for staging and follow-up of lymphoma treatment.
Clear documentation of findings related to extranodal sites is crucial.
Used during treatment of follicular lymphoma grade III.
Document the specific chemotherapy regimen and patient response.
Oncology specialists must ensure accurate coding of chemotherapy administration.
Key symptoms include B-symptoms such as fever, night sweats, and unexplained weight loss, along with lymphadenopathy and possible extranodal involvement.